269 related articles for article (PubMed ID: 25011439)
1. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
[TBL] [Abstract][Full Text] [Related]
2. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
[TBL] [Abstract][Full Text] [Related]
3. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
4. Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.
Virdee PS; Moschandreas J; Gebski V; Love SB; Francis EA; Wasan HS; van Hazel G; Gibbs P; Sharma RA
JMIR Res Protoc; 2017 Mar; 6(3):e43. PubMed ID: 28351831
[TBL] [Abstract][Full Text] [Related]
5. Selective internal radiation therapy for liver metastases from colorectal cancer.
Townsend AR; Chong LC; Karapetis C; Price TJ
Cancer Treat Rev; 2016 Nov; 50():148-154. PubMed ID: 27690234
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
Wolstenholme J; Fusco F; Gray AM; Moschandreas J; Virdee PS; Love S; Van Hazel G; Gibbs P; Wasan HS; Sharma RA
Int J Cancer; 2020 Aug; 147(4):1078-1085. PubMed ID: 31840815
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
Sharma RA; Van Hazel GA; Morgan B; Berry DP; Blanshard K; Price D; Bower G; Shannon JA; Gibbs P; Steward WP
J Clin Oncol; 2007 Mar; 25(9):1099-106. PubMed ID: 17369573
[TBL] [Abstract][Full Text] [Related]
8. Selective internal radiation therapy for liver metastases from colorectal cancer.
Townsend A; Price T; Karapetis C
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007045. PubMed ID: 19821394
[TBL] [Abstract][Full Text] [Related]
9. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
van Hazel GA; Heinemann V; Sharma NK; Findlay MP; Ricke J; Peeters M; Perez D; Robinson BA; Strickland AH; Ferguson T; Rodríguez J; Kröning H; Wolf I; Ganju V; Walpole E; Boucher E; Tichler T; Shacham-Shmueli E; Powell A; Eliadis P; Isaacs R; Price D; Moeslein F; Taieb J; Bower G; Gebski V; Van Buskirk M; Cade DN; Thurston K; Gibbs P
J Clin Oncol; 2016 May; 34(15):1723-31. PubMed ID: 26903575
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres.
Winter H; Rassam J; Virdee PS; Goldin R; Pitcheshwar P; Weaver K; Primrose J; Berry DP; Wasan HS; Sharma RA
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31408970
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.
Gibbs P; Do C; Lipton L; Cade DN; Tapner MJ; Price D; Bower GD; Dowling R; Lichtenstein M; van Hazel GA
BMC Cancer; 2015 Oct; 15():802. PubMed ID: 26503593
[TBL] [Abstract][Full Text] [Related]
15. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
[TBL] [Abstract][Full Text] [Related]
16. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
17. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
19. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
20. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
